Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky
Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litigation risk before the losses occurred. NEW YORK, Oct. 12, 2026...
Covered in this story
Analyst targets on Liquidia Corp
- Raymond James: $28 → $53 by Oct 2027 · Outperform via Investing.com
- Wells Fargo: $28.6 → $30 by Oct 2027 · Equal Weight via Seeking Alpha
- H.C. Wainwright: $28.6 → $58 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $LQDA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Liquidia Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.